Completed OBSERVATIONAL NCT04226378

Canadian Real-World Outcomes of Omnipod Initiation in People With T1D (COPPER)

Canadian Real-World Outcomes of Omnipod Initiation in People With T1D: Evidence From the LMC Diabetes Registry: The COPPER Study

Sponsor: Insulet Corporation

Conditions Diabetes Mellitus, Type 1

Interventions MDI Omnipod

Updated 5 times since 2020 Last updated: Feb 19, 2020 Started: Jan 20, 2020 Primary completion: Feb 9, 2020 Completion: Feb 9, 2020

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT04226378, this observational or N/A phase trial focuses on Diabetes Mellitus, Type 1 and remains completed. Sponsored by Insulet Corporation, it has been updated 5 times since 2020, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed
Jul 2024 — Sep 2024 [monthly]

Completed
Jan 2021 — Jul 2024 [monthly]

Completed
Mar 2020 — Jan 2021 [monthly]

Completed

Status: Active Not Recruiting → Completed
Feb 2020 — Mar 2020 [monthly]

Active Not Recruiting

First recorded

Jan 2020

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Insulet Corporation
LMC Diabetes & Endocrinology Ltd.

Data source: LMC Diabetes & Endocrinology Ltd.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Toronto, Canada